Approved for use through 9/73/12006, ONS

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF CI.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it confairs a valid OMB cont.

U.S.PATENTS

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

	Application Number		10666503		
	Filing Date		2003-09-19		
	First Named Inventor Jen		in CHAO		
	Art Unit		2164		
	Examiner Name	Bell, (	Cory C.		
	Attorney Docket Number		252011-1660		

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue E	Date	of cited Document		Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear			
	1	5546579		1996-08	l-13	Josten et al.					
If you wis	h to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	lease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Cite   Publication Number   Kind   Publication   Date		tion	of cited Decument Releva			s,Columns,Lines where ant Passages or Relevant is Appear					
	1	20020064209	2002-05-30 Turetzky et al.								
	2	20020024463		2002-02-28		Turetzky et al.					
	3	20030187961		2003-10	1-02	Kamata					
If you wis	h to a	dd additional U.S. Publi:	shed Ap	plication	citatio	n information p	olease click the Ad	d button	Add		_
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*			Kind Code <sup>4</sup>	Publication Date	Name of Patente Applicant of cited Document	e or	vhere Rel	or Relevant	Ts		
	1	WO 9634486	wo			1996-10-31	Thomas et al.				

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

pplication Number		10666503
iling Date		2003-09-19
irst Named Inventor Jen-Li		in CHAO
rt Unit		2164
xaminer Name Bell, C		Cory C.
Hornou Docket Number		252011-1660

If you wish to add additional Foreign Patent Document citation information please click the Add button Add NON-PATENT LITERATURE DOCUMENTS Remove									
									Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Initials* No No analysis of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Initials* of the Article (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(symbolisher, city and/or country where publisher.
1 Singapore Search Report mailed March 2, 2007									
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button Add								
	EXAMINER SIGNATURE								
Examiner	Examiner Signature Date Considered								
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

1 See Kinz Code of USPTO Platent Documents at year, <u>USPTO CODE</u> or MEPP 910.4. <sup>2</sup> Either office that issued the document, by the ho-lefter code (WPO Standard 513.). <sup>2</sup> The Japanese parted converset, the includion to be year of the reign or the Either code to be self in unbred for papert document. <sup>2</sup> Kind of document by the appropriate symbols as indicated on the document under WPO Standard 51.16 if goostile. <sup>3</sup> Applicant is to place a check mark their figurity integrates precision as standard.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10666503		
Filing Date		2003-09-19		
First Named Inventor	Jen-L	in CHAO		
Art Unit		2164		
Examiner Name	Bell, 0	Cory C.		
Attorney Docket Number		252011-1660		

#### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign papel patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

- That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/97(c).
- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Daniel R. McClure/	Date (YYYY-MM-DD)	2007-04-03
Name/Print	Daniel R. McClure	Registration Number	38.962

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) and application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bs 1449, Alexandrin, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bs 1459, Alexandria, V.S. 2311-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.